Annexon Biosciences

Annexon Biosciences is a clinical-stage biopharmaceutical company founded in 2011, with a focus on developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company's pipeline consists of innovative product candidates, namely ANX005 for intravenous administration, ANX007 for intravitreal administration, and ANX009 for subcutaneous administration, all designed to block the activity of C1q and the entire classical complement pathway. Annexon is leveraging a disciplined, biomarker-driven strategy to enhance the probability of technical success of its portfolio. The company recently received a noteworthy $125.00MPost-IPO Equity investment at 20 December 2023. Annexon's mission revolves around "Unlocking the Next Generation of Complement Therapies", and its efforts are centered in the United States. For more information, visit www.annexonbio.com.